THE BUSINESS OF BIOTECH
55:16
![Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho]( "Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho")
Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma.
ABOUT THE BUSINESS OF BIOTECH
Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success.
MEET YOUR HOST
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute.
Interested in joining us on air? Contact us
RECENT EPISODES
FINANCE & CAPITAL MARKETS
DISCOVERY
35:53
![24_01_BoB_1280x720_Ep12]( "24_01_BoB_1280x720_Ep12")
